Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EX110
- Development stage
- Preclinical
- Lead developer
- Excelmab
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
EX110 is a preclinical-stage trispecific antibody being developed by Guangzhou Excelmab. As of 2024, the specific molecular targets and therapeutic indications for EX110 have not been publicly disclosed by the company. It is part of a broader pipeline of multi-specific antibodies generated using Excelmab's proprietary engineering platforms, which aim to create next-generation biologics with improved binding properties and therapeutic windows for the treatment of cancer or other immune-related conditions.
02
Targets
CD3 (T-cell surface glycoprotein CD3)DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on EX110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EX110.